Operating Expenses Summary of Zealand Pharma A/S

Zealand Pharma A/S's latest annual operating expenses in 2023 was 226.92 Million DKK , down -6.96% from previous year.
Zealand Pharma A/S's latest quarterly operating expenses in 2024 Q2 was 285.55 Million DKK , up 12.55% from previous quarter.
Zealand Pharma A/S reported a annual operating expenses of 920.58 Million DKK in annual operating expenses 2022, down -24.79% from previous year.
Zealand Pharma A/S reported a annual operating expenses of 1.22 Billion DKK in annual operating expenses 2021, up 12.13% from previous year.
Zealand Pharma A/S reported a quarterly operating expenses of 259.71 Million DKK for 2024 Q1, up 3.2% from previous quarter.
Zealand Pharma A/S reported a quarterly operating expenses of 251.64 Million DKK for 2023 Q4, up 2.05% from previous quarter.

Annual Operating Expenses Chart of Zealand Pharma A/S (2023 - 2007)

Historical Annual Operating Expenses of Zealand Pharma A/S (2023 - 2007)

Year	Operating Expenses	Operating Expenses Growth
2023	226.92 Million DKK	-6.96%
2022	920.58 Million DKK	-24.79%
2021	1.22 Billion DKK	12.13%
2020	1.09 Billion DKK	73.57%
2019	628.86 Million DKK	21.97%
2018	515.58 Million DKK	38.77%
2017	371.53 Million DKK	16.48%
2016	318.96 Million DKK	29.27%
2015	246.73 Million DKK	15.55%
2014	213.53 Million DKK	11.61%
2013	191.32 Million DKK	9.18%
2012	175.23 Million DKK	31.35%
2011	133.4 Million DKK	-31.95%
2010	196.05 Million DKK	86.28%
2009	105.24 Million DKK	4.25%
2008	100.95 Million DKK	-17.56%
2007	122.44 Million DKK	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	285.55 Million DKK	12.55%
2024 Q1	259.71 Million DKK	3.2%
2023 Q4	251.64 Million DKK	2.05%
2023 FY	856.54 Million DKK	-6.96%
2023 Q2	210.97 Million DKK	11.41%
2023 Q3	246.59 Million DKK	16.88%
2023 Q1	189.36 Million DKK	-27.97%
2022 Q2	265.08 Million DKK	11.57%
2022 Q4	262.9 Million DKK	28.11%
2022 FY	920.58 Million DKK	-24.79%
2022 Q1	237.58 Million DKK	-25.23%
2022 Q3	205.21 Million DKK	-22.58%
2021 Q4	317.75 Million DKK	9.74%
2021 Q1	284.97 Million DKK	-24.62%
2021 Q3	289.53 Million DKK	-12.71%
2021 FY	1.22 Billion DKK	12.13%
2021 Q2	331.68 Million DKK	16.39%
2020 FY	1.09 Billion DKK	73.57%
2020 Q2	246.7 Million DKK	30.1%
2020 Q3	277.15 Million DKK	12.34%
2020 Q4	378.03 Million DKK	36.4%
2020 Q1	189.62 Million DKK	-3.89%
2019 Q3	139.75 Million DKK	-10.43%
2019 Q4	197.3 Million DKK	41.18%
2019 FY	628.86 Million DKK	21.97%
2019 Q1	135.78 Million DKK	620.82%
2019 Q2	156.02 Million DKK	14.9%
2018 Q2	145.02 Million DKK	57.84%
2018 FY	515.58 Million DKK	38.77%
2018 Q1	91.88 Million DKK	-23.32%
2018 Q4	-26.07 Million DKK	-108.55%
2018 Q3	304.75 Million DKK	110.14%
2017 Q2	104.34 Million DKK	48.08%
2017 FY	371.53 Million DKK	16.48%
2017 Q3	76.89 Million DKK	-26.3%
2017 Q4	119.82 Million DKK	55.83%
2017 Q1	70.46 Million DKK	-28.17%
2016 Q4	98.09 Million DKK	76.93%
2016 Q1	70.31 Million DKK	-0.35%
2016 FY	318.96 Million DKK	29.27%
2016 Q3	55.44 Million DKK	-41.7%
2016 Q2	95.1 Million DKK	35.26%
2015 Q2	70.7 Million DKK	28.57%
2015 FY	246.73 Million DKK	15.55%
2015 Q1	54.99 Million DKK	-25.02%
2015 Q4	70.55 Million DKK	39.79%
2015 Q3	50.47 Million DKK	-28.62%
2014 Q3	43.44 Million DKK	-16.18%
2014 Q2	51.82 Million DKK	15.38%
2014 Q1	44.91 Million DKK	-6.72%
2014 FY	213.53 Million DKK	11.61%
2014 Q4	73.35 Million DKK	68.86%
2013 Q3	37 Million DKK	-23.3%
2013 Q2	48.24 Million DKK	-16.69%
2013 Q1	57.91 Million DKK	5.32%
2013 FY	191.32 Million DKK	9.18%
2013 Q4	48.15 Million DKK	30.12%
2012 Q3	37.4 Million DKK	-13.93%
2012 FY	175.23 Million DKK	31.35%
2012 Q4	54.98 Million DKK	47.0%
2012 Q1	39.38 Million DKK	-7.61%
2012 Q2	43.45 Million DKK	10.36%
2011 Q3	19.88 Million DKK	-27.9%
2011 Q1	43.31 Million DKK	-35.18%
2011 FY	133.4 Million DKK	-31.95%
2011 Q4	42.62 Million DKK	114.33%
2011 Q2	27.58 Million DKK	-36.32%
2010 Q1	25.67 Million DKK	0.0%
2010 Q4	66.81 Million DKK	28.1%
2010 Q3	52.16 Million DKK	1.47%
2010 Q2	51.4 Million DKK	100.22%
2010 FY	196.05 Million DKK	86.28%
2009 FY	105.24 Million DKK	4.25%
2008 FY	100.95 Million DKK	-17.56%
2007 FY	122.44 Million DKK	0.0%

Peer Operating Expenses Comparison of Zealand Pharma A/S

Name	Operating Expenses	Operating Expenses Difference
ALK-Abelló A/S	2.36 Billion DKK	90.421%
Bavarian Nordic A/S	3.02 Billion DKK	92.496%
Genmab A/S	10.92 Billion DKK	97.923%
Gubra A/S	164.35 Million DKK	-38.074%
Novo Nordisk A/S	93.92 Billion DKK	99.758%
Orphazyme A/S	27.04 Thousand DKK	-839103.432%
Pharma Equity Group A/S	24.81 Million DKK	-814.557%

Global Stocks Search

Zealand Pharma A/S (ZEAL.CO)

Operating Expenses Summary of Zealand Pharma A/S

Annual Operating Expenses Chart of Zealand Pharma A/S (2023 - 2007)

Historical Annual Operating Expenses of Zealand Pharma A/S (2023 - 2007)

Peer Operating Expenses Comparison of Zealand Pharma A/S